DPP4 and type 2 diabetes mellitus: Repositioning of gliptins, a class of drugs primarily used to treat type 2 diabetes by inhibiting the activity of dipeptidyl peptidase-4 (DPP-4), is being investigated for their potential neuroprotective effects.